Epigenomics' Q1 Revenues Rise, Net Loss Declines | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today reported that its first-quarter revenues increased 36 percent due primarily to milestone payments received from Abbott and new collaborations, and its net loss dropped 16 percent year over year.

The German molecular diagnostics firm reported total revenues of €1.24 million (US$1.7 million), up 36 percent from €920,000 for the first quarter of 2008. Its diagnostics business accounted for 70 percent of its total revenue, while its biomarker service revenue accounted for 30 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.